Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system

Hu, Fuqiang; Jiang, Saiping; Du, Yong‐Zhong; Yuan, Hong; Ye, Yi-Qing; Zeng, Su

doi:10.1016/j.colsurfb.2005.08.005

Cited by 445 publications

(269 citation statements)

References 23 publications

Supporting

Mentioning

222

Contrasting

Unclassified

Order By: Relevance

“…It has been reported that NLC have good drug-loading capability [31] . The lipophilicity of the drug is closely related to its incorporation [32,33] . Thus, a high breviscapine encapsulation efficiency was successfully achieved in our study due to the formation of an ionic complex.…”

Section: Discussionmentioning

confidence: 99%

Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine

Zheng

Shan

et al. 2013

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: Breviscapine isolated from the Chinese herb Erigeron breviscapus (Vant) Hand-Mazz is widely used to treat cardiovascular and cerebrovascular diseases. The aim of this study was to improve the pharmacokinetic profiles of breviscapine using nanostructured lipid carrier based on an ionic complex formation. Methods: Breviscapine nanostructured lipid carrier (Bre-NLC) was prepared using the thin film homogenization method. The morphology of Bre-NLCs was determined using transmission electron microscopy. The mean particle size, polydispersity index, zeta-potential analysis and entrapment efficiency were analized. In vitro release was studied using the dialysis method. In vitro stability was studied in fresh plasma and liver slurry of rats. In vivo pharmacokinetics was analyzed in rats after intravenous injection of a dose equivalent to breviscapine (10 mg/kg). Results: The Bre-NLCs were spherical with a mean particle size of ~170 nm, a zeta potential of ~20 mV and a high entrapment efficiency of ~89%. Compared with a commercially available solution, a substantial decrease in the cumulative release of breviscapine was found for the Bre-NLCs. The NLC has a significantly protective effect against the liver enzyme degradation of breviscapine. After intravenous administration in rats, the Bre-NLCs exhibited a 32 times increase in the AUC 0-t and a 12 times increase in T 1/2 as compared to the commercially available breviscapine solution. Conclusion:The results demonstrate that the NLC has great potential to use as a novel sustained release system for breviscapine.

show abstract

Section: Discussionmentioning

confidence: 99%

Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine

Zheng

Shan

et al. 2013

Acta Pharmacol Sin

View full text Add to dashboard Cite

show abstract

“…In comparison to SLNs, NLCs have better drug entrapment efficiency, release profile, and have more imperfections in the crystal structures, which improve their stability and drug retention upon storage (Jenning et al, 2000;Hu et al, 2005;Shen et al, 2010).…”

Section: Incorporation Of Liquid Lipid In Slns For Ocular Drug Delivementioning

confidence: 99%

Solid lipid nanoparticles for ocular drug delivery

2010

View full text Add to dashboard Cite

“…This notion previously has been shown (Abdelbary & Fahmy, 2009). This fact may attribute to the reduction of surface tension with higher lipophilic surfactant content that may lead to smaller particles (Hu et al, 2005). However, it should be considered that formulation of SLNs with higher concentration of surfactant (!…”

Section: Discussionmentioning

confidence: 99%

Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles

Eskandani

Barar

Dolatabadi

et al. 2015

Pharmaceutical Biology

View full text Add to dashboard Cite

Context: Galbanic acid (GBA) is a sesquiterpene coumarin with different medicinal properties and anticancer effects. Objective: To improve the anticancer activities of GBA, in the current study, we aimed to fabricate GBA-loaded solid lipid nanoparticles (GBA-SLNs) and study their biological activities in vitro. Materials and methods: Hot homogenization was used for preparation of GBA-SLNs. The encapsulation efficiency (EE) and drug loading (DL) and in vitro release were determined. MTT, DAPI, DNA fragmentation, comet, and Anexin V apoptosis assays were used to compare the anti-cell proliferation and genotoxicity properties of GBA and GBA-SLNs against A549 cells and HUVEC to detect apoptosis and DNA damage in the final concentration of 100 mM after 48 h treatment. Results: Scanning electron microscopy (SEM) and particle size analysis showed spherical SLNs (92 nm), monodispersed distribution, and zeta potential of À23.39 mV. High EE (498%) and long-term in vitro release were achieved. The stability of GBA-SLNs in aqueous medium was approved after 3 months in terms of size and polydispersity index. GBA was able to inhibit A549 growth with an IC 50 value of 62 mM at 48 h. Although GBA-SLNs could also inhibit the growth rate of A549 cells, the effect is perceived after 48 h, as approved by the quantitative expression of Bcl-xL and Casp 9 genes, and also genotoxicity assays. Conclusion: Long-term apoptotic effect of GBA-SLNs compared with GBA may be due to the accumulation of GBA-SLNs in the tumor site because of deviant tumor pathology. Our data confirmed that SLNs could be exploited for sustained lipophilic GBA delivery.

show abstract

Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system

Cited by 445 publications

References 23 publications

Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine

Development of ionic-complex-based nanostructured lipid carriers to improve the pharmacokinetic profiles of breviscapine

Solid lipid nanoparticles for ocular drug delivery

Formulation, characterization, and geno/cytotoxicity studies of galbanic acid-loaded solid lipid nanoparticles

Contact Info

Product

Resources

About